Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Published Online: 2018-01-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Alessio Schirone•Angelo Di Leo•Bharani Dharan•Dalila Sellami•Daniel Egle•Denis Weber•Dimitar Kalev•Eva Ciruelos•Keun Seok Lee•Marie-Ange Mouret-Reynier•Mona El-Hashimy•Per E Lønning•Roberto Bordonaro•Ruth O'Regan•Sibel Blau•Stephen Johnston•Thomas Bachelot•Thomas Decker•Tibor Csőszi•Vivianne C G Tjan-Heijnen•Wolfgang Janni
